Alkermes (ALKS) Stock Forecast & Price Target

Alkermes is attractive because its core business remains profitable and supports more than $300M of adjusted EBITDA, while management still expects profitability and rapid deleveraging even as R&D rises. The orexin franchise adds meaningful upside: alixorexton has shown clinically meaningful efficacy across NT1, NT2, and idiopathic hypersomnia, with a split-dose strategy intended to improve late-day coverage and strengthen the upcoming year-end '26 IH readout and summer-'27 narcolepsy data. In addition, ALKS 7290 delivered first clinical proof-of-concept beyond sleep-wake disorders in ADHD, with no serious TEAEs in a small N=50 study and a 2027 phase 2 readout, reinforcing the platform’s optionality and commercial breadth.

Alkermes is facing a negative setup because its royalty and proprietary product base may keep eroding through the remainder of the decade, while rapid generic and competitive pressure could weigh on the injectable franchise, including Vivitrol. The orexin program remains too early to underwrite with conviction, as efficacy and safety still need validation in larger studies, and the company also carries meaningful exposure to Medicaid, plus regulatory, manufacturing, and commercialization risks that could hurt earnings and cash flow. Investors therefore face a combination of pipeline uncertainty, possible FDA or clinical setbacks, and the need for cost cuts or dilutive financing if R&D and SG&A outlays remain heavy.